Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.54 |
| ▸ | CCR2 | P41597 | 2/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401649 | 0.88 | PIK3CD (0.55) | PIK3CDCHEK2ROCK2CCR2ROCK1 | |
| SCHEMBL5407821 | 0.86 | CYP4A11 (0.59) | PIK3CDCHEK2ROCK2CCR2ROCK1 | |
| SCHEMBL5412560 | 0.85 | ROCK2 (0.62) | PIK3CDCHEK2ROCK2CCR2ROCK1 | |
| SCHEMBL24093960 | 0.85 | CHEK2 (0.57) | PIK3CDCHEK2ROCK2CYP4A11CYP4F2 | |
| SCHEMBL5817971 | 0.80 | ROCK2 (0.64) | ROCK2CCR2ROCK1 | |
| SCHEMBL5404376 | 0.80 | ROCK2 (0.54) | CHEK2ROCK2CCR2ROCK1CYP4A11 | |
| SCHEMBL5416839 | 0.79 | PIK3CD (0.47) | PIK3CDCHEK2PRMT5IDO1TDO2 | |
| SCHEMBL21604523 | 0.79 | CHEK2 (0.55) | PIK3CDCHEK2GPR119PDE4BUSP30 | |
| SCHEMBL20281619 | 0.79 | CHEK2 (0.55) | PIK3CDCHEK2GPR119PDE4BUSP30 | |
| SCHEMBL20281604 | 0.79 | CHEK2 (0.55) | PIK3CDCHEK2GPR119PDE4BUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | PIK3CD 439/4885CHEK2 2372/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.